Company intelligence / Profile preview
Xiamen Innovax Biotech Co., Ltd.
Xiamen, Fujian, Chinainnovax.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Innovax has successfully developed and commercialized the world's first Hepatitis E Vaccine (Hecolin®) launched in China in 2012, and a Cervical Cancer Vaccine (Cecolin® - HPV16&18 bivalent) approved in 2019. Their 9-valent HPV vaccine is currently in Phase III clinical trials[1][7][8].
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- Recombinant vaccinesVirus-like particle vaccinesGenetically engineered subunit vaccinesConjugated vaccines
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Partnerships
GSK (formerly GlaxoSmithKline)Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Xiamen University
Beyond the preview
Go deeper on Xiamen Innovax Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiamen Innovax Biotech Co., Ltd..